Carbon dioxide intranasal - Capnia

Drug Profile

Carbon dioxide intranasal - Capnia

Alternative Names: Serenz; Serenz Allergy Relief

Latest Information Update: 13 May 2016

Price : $50

At a glance

  • Originator Capnia
  • Class Inorganic carbon compounds; Oxides
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Trigeminal neuralgia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Allergic rhinitis; Cluster headache; Trigeminal neuralgia

Most Recent Events

  • 13 May 2016 9195736 - added trial Phase II TN description
  • 21 Dec 2015 Carbon dioxide intranasal - Capnia receives Orphan Drug status for Trigeminal neuralgia in USA
  • 01 Sep 2015 Phase-II clinical trials in Trigeminal neuralgia in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top